Diagnosis and treatment of malignant neoplasms
AssigneeRhode Island Hospital
InventorsJack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
Life of this patent
Estimating the term…
Abstract
The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.
Claims20
A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily fluid from said mammal with an antibody or fragment thereof which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein an increase in antigen-antibody complex indicates an increase in HAAH level compared to a normal noncancerous control, said increase being indicative of a malignant neoplasm and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.
A method for prognosis of a malignant neoplasm of a mammal, comprising:
- contacting a bodily fluid from said mammal with an antibody or fragment thereof which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex;
- quantitating the amount of complex to determine the level of HAAH in said fluid;
- and
- comparing the level of HAAH in said fluid with a normal noncancerous control level of HAAH, wherein increasing levels of HAAH over time indicates an adverse prognosis, and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.
A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily tissue from said mammal with an antibody or fragment thereof which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein an increase in antigen-antibody complex indicates an increase in HAAH level compared to a normal noncancerous control, said increase being indicative of a malignant neoplasm, wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386, and wherein said fragment of said monoclonal antibody is a single chain Fv molecule.
Dependencies are inferred from the claim text.